The FDA is changing the rules on orphan drugs, according to a story on NPR. Makers of orphan drugs – which are developed for rare diseases that affect less than 200,000 people – get special treatment from the FDA, such as tax credits, waivers of fees and a seven-year monopoly on the drug. But orphan drugs can command huge price tags to consumers, and an investigation is under way after critics said some of the orphans — such as the psychopharmaceutical Abilify — were already licensed for common use by the FDA. New Commissioner Scott Gottlieb also announced other measures to be implemented.